Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest treatment of obesity Stories

2013-09-24 08:30:54

- Personalized medicine approach to treat obesity caused by MC4R genetic deficiency - BOSTON, Sept. 24, 2013 /PRNewswire/ -- Rhythm announced today the initiation of the first of a series of clinical trials with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity in individuals with a genetic deficiency in the MC4R pathway. "Genes with loss of function in the MC4 pathway result in severe obesity, with a prevalence that may exceed one...

2013-08-27 08:27:00

SAN DIEGO, Aug. 27, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Light Study independent Data Monitoring Committee has recently confirmed that sufficient major adverse cardiovascular events (MACE) are expected to occur within the next two months, enabling the interim analysis to be conducted by early December and the potential resubmission of the Contrave® New Drug...

2013-03-13 16:26:05

SAN DIEGO, March 13, 2013 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the fourth quarter and year ended December 31, 2012. Three months ended December 31, 2012For the three months ended December 31, 2012, Orexigen reported a net loss of $32.5 million, or $0.41 per share, as compared to a net loss of $4.3 million, or $0.09 per share, for the fourth quarter of 2011....

2013-02-06 23:04:22

For practitioners of weight loss programs in Bakersfield, CA there is none more devoted than Dr. Jan Trobisch of Synergy Lifestyle Center–the board certified specialist is celebrating one year as a member of the American Society of Bariatric Physicians. Bakersfield, CA (PRWEB) February 06, 2013 Dr. Jan Trobisch, Internist and founder of Synergy Lifestyle Center, a Bakersfield, CA medical weight loss facility is celebrating one year as a member of the American Society of Bariatric...

2013-01-04 08:22:19

BOSTON, Jan. 4, 2013 /PRNewswire/ -- Rhythm announced today the initiation of a Phase 2 clinical trial with RM-493, the company's novel melanocortin 4 receptor (MC4R) agonist, for the treatment of obesity. "This Phase 2 study will greatly expand our understanding of RM-493's profile for the treatment of obesity," said Liz Stoner, MD, Chief Development Officer of Rhythm. "Based on the data from preclinical studies and early clinical trials, we believe RM-493 has substantial therapeutic...

2012-12-04 08:28:41

PARIS, December 4, 2012 /PRNewswire/ -- ObeTherapy, a company focusing on the treatment of obesity and type II diabetes, announces the publication of results that validate a new therapeutic target associated with "starvation" human phenotype and a novel small-molecule candidate for the treatment of obesity and type II diabetes, The article, entitled: Enteropeptidase: a gene associated with a starvation human phenotype and a novel target for obesity treatment,...

2012-11-07 16:27:31

SAN DIEGO, Nov. 7, 2012 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the third quarter of 2012. For the three months ended September 30, 2012, Orexigen reported a net loss of $30.6 million, or $0.44 per share, as compared to a net loss of $4.6 million, or $0.10 per share, for the third quarter of 2011. As of September 30, 2012, Orexigen had $56.1 million in cash...

2012-09-07 02:23:38

CRANBURY, N.J., Sept. 7, 2012 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN) today announced that its collaboration partner, AstraZeneca, has decided to discontinue further development of AZD2820, one of a number of collaboration compounds in various stages of development for the treatment of obesity. AstraZeneca remains committed to this collaboration program and to the continued advancement of melanocortin agonists for treatment of obesity. AZD2820, a...

2012-08-07 02:28:36

SAN DIEGO, Aug. 7, 2012 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced financial results for the second quarter of 2012. For the three months ended June 30, 2012, Orexigen reported a net loss of $16.7 million, or $0.25 per share, as compared to a net loss of $7.6 million, or $0.16 per share, for the second quarter of 2011. As of June 30, 2012, Orexigen had $67.4 million in cash and cash...

2012-06-26 10:24:47

Study shows potential weight-loss medication helps overweight patients with diabetes SILVER SPRING, Md., June 26, 2012 /PRNewswire-USNewswire/ -- A new study on the effects of lorcaserin, a drug recently recommended for approval by an FDA advisory panel for the treatment of obesity, was just published in the scientific journal Obesity. The journal is published by The Obesity Society (TOS), the leading scientific organization in North America dedicated to the study of obesity. Authors...